What Is Selank? Anxiety Research, Effects and Human Evidence

Apex Laboratory · Compound explained · Evidence checked September 8, 2026

Selank is a synthetic seven-amino-acid peptide studied mainly for anxiety-related effects. Small human studies have reported improvements, alongside laboratory work on brain signaling. The evidence is more limited than a proven treatment for everyday stress, and the name on a research vial does not make it equivalent to a medicine studied in a clinic.

Written by Nicholas Tremelling. Reviewed by the Apex Laboratory Editorial Team under our editorial standards.

What is Selank, and how is it related to tuftsin?

Selank has the sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro, often written TKPRPGP. Its first four residues match tuftsin; the final Pro–Gly–Pro segment extends that sequence. Tuftsin is an immune-related peptide, but a structural relationship does not make every tuftsin finding a Selank finding. Primary sequence and enzyme study · Comparative tuftsin-family research.

The parent reference in PubChem has formula C₃₃H₅₇N₁₁O₉ and molecular weight about 751.9 g/mol. A salt, such as an acetate form, adds another identity detail. “Selank,” “Selank acetate” and a modified name such as “N-acetyl Selank” should not be assumed to describe identical material or an interchangeable evidence base.

Does Selank help anxiety? What the human studies show

The published comparisons studied people with diagnosed anxiety-related disorders. Their comparators were active medicines, rather than an inert placebo. The later papers describe open studies, so participants and investigators were not blinded to treatment. That matters when outcomes include symptom ratings and reported tolerability.

These are separate study designs, not one pooled clinical trial. The 2014 and 2015 reports share investigators and clinical centers. More independent replication would strengthen confidence.

The follow-up date changes the headline

Likewise, the 2015 trial’s later findings need their actual design: half of the combination group continued Selank after phenazepam ended. Continued treatment and observation after stopping are different questions. Its full report supplies that detail, which is easy to lose in a short summary.

What did the human brain-imaging study measure?

A 2020 study included 52 healthy participants across Selank, Semax and placebo groups. Researchers measured resting brain-network connectivity before administration and at 5 and 20 minutes afterward. They found differences involving the right amygdala and temporal brain regions. Panikratova and colleagues.

This demonstrates a measured brain signal under the study conditions. It does not mean 52 people received Selank, prove anxiety relief within five minutes, or show better memory in ordinary daily life. Imaging, symptoms and task performance are different endpoints.

How does Selank work? GABA is a clue, not the whole answer

GABA is a major inhibitory messenger in the brain. Researchers have investigated whether Selank changes how parts of the GABA system function. A radioligand study reported modulation of GABA binding in isolated membrane preparations; another found altered inhibitory synaptic currents in rat hippocampal slices. Those experiments support a mechanism worth investigating. They do not establish that Selank is simply a direct GABA agonist or a benzodiazepine without its risks. Binding study · Synaptic-current study.

Another proposed mechanism involves enkephalins, short signaling peptides. Selank inhibited their breakdown in a human-plasma enzyme experiment. The measured enkephalin half-life in that work is not Selank’s own elimination half-life. Enkephalin study.

What about memory, BDNF and cortisol?

BDNF is involved in neuronal function and plasticity, but “more BDNF” is not a sufficient description of Selank’s evidence. In rats exposed to alcohol over a prolonged period, Selank prevented memory-related disturbances and prevented an alcohol-associated increase in BDNF in the measured brain regions. The direction depended on the model. It is not evidence of universally increasing BDNF or improving human cognition. Kolik and colleagues, 2019.

Laboratory stress behavior also needs context. A rat study found that the repeated administration procedure itself worsened anxiety-related measures even without the planned chronic stress. Responses to Selank, diazepam and their combination differed between those conditions. A simple “reduces stress” label loses that experimental detail. Primary behavioral study.

The human studies reviewed here do not establish a reproducible cortisol-lowering effect. Feeling less anxious, changing a brain-network signal and lowering a particular hormone are separate claims. None should be substituted for another.

How quickly does Selank work, and what is its half-life?

There is no single defensible number that combines all of the measurements below. A fast biological observation does not establish fast clinical relief, and a later symptom assessment does not measure how long the original peptide remains in blood.

Labeled-peptide metabolism study · Rat distribution study. These sources provide analytical and animal information, not a personal administration schedule.

Side effects, withdrawal and interactions: what remains uncertain?

The small clinical comparisons reported favorable tolerability relative to their particular comparators. That does not establish the frequency of uncommon adverse events, safety with long-term exposure, or equivalence between clinical material and products sold under similar names. The open designs and short follow-up also matter.

Experiments combining Selank with other signaling drugs show that interactions can be complex. A favorable finding with a clinician-managed comparator or a cell culture does not establish that mixing products is safe. The existing studies cannot predict whether a particular person would feel calm, stimulated, sleepy or unchanged.

Immune effects are also more complicated than an “immune boost.” One human blood-cell study reported suppression of IL-6 gene expression alongside increased measured IL-6 concentration under the reported conditions. Gene expression and measured protein concentration are not interchangeable outcomes, and those results do not demonstrate infection prevention. Primary immune-marker report.

Is Selank FDA approved?

Selank is not an FDA-approved medicine. The approval-database search under Selank returned no matching record. FDA currently lists Selank acetate (TP-7) in its table of substances nominated but withdrawn, and flags potential immunogenicity associated with aggregation or peptide-related impurities and missing safety information. Withdrawal from a nomination process is not approval. Current FDA source.

The September 8, 2026 literature review included 70 exact-name PubMed title/abstract records. Broad registry searches also returned unrelated studies because “TP7” can name an electrode location. Inspection did not identify a Selank intervention trial in the returned ClinicalTrials.gov records. This dated search finding does not erase the published human comparisons or claim to cover every registry and unpublished study worldwide.

How is Selank different from Semax?

They are different peptides with different sequence origins and research histories. The human imaging paper compared separate groups; it did not test a combined Selank–Semax product. For the detailed side-by-side evidence and identity comparison, use the Selank and Semax research comparison. Shared interest in brain signaling does not establish an additive benefit or an appropriate combination.

What should a research-material record tell you?

Start with the exact sequence and form, then the labeled configuration, sample identity and stated analytical methods. A name on a package cannot establish those fields. Researchers have used mass-spectrometry methods to identify Selank and other peptides in unknown preparations; that is a material-identification task, distinct from demonstrating human effectiveness. Primary analytical study.

Frequently Asked Questions About Selank

What is Selank?

Selank is a synthetic peptide containing seven amino acids. It extends the four-residue tuftsin sequence with Pro–Gly–Pro and has been investigated for anxiety-related effects. A sequence relationship does not make Selank equivalent to tuftsin, Semax or a modified Selank analogue.

Does Selank help with anxiety?

Small human comparisons reported improvements in anxiety-related symptoms. They used active comparators, and the later studies were open rather than blinded. Results varied by measurement and follow-up time. They provide an early clinical signal, not a reliable prediction of individual benefit.

What does Selank feel like?

There is no established feeling that everyone should expect. Small clinical reports describe changes in anxiety, fatigue-related symptoms and tolerability, but cannot predict whether an individual would feel calm, stimulated, sleepy or unchanged. Online experiences do not provide a controlled comparison.

How quickly does Selank work?

A human imaging experiment measured brain-network changes at five and twenty minutes, but did not establish anxiety relief at those times. The clinical comparisons assessed symptoms over days. These are different outcomes and cannot be combined into a guaranteed onset time.

What is the half-life of Selank?

The sources reviewed here do not establish a validated human elimination half-life that applies to a retail Selank product. Studies of peptide breakdown products, rat tissue distribution and enkephalin breakdown measure different things. A symptom reported at follow-up is not a measurement of peptide half-life.

Is Selank a GABA agonist?

Laboratory studies suggest that Selank can modulate aspects of GABA signaling, including binding and inhibitory synaptic activity. Other experiments found context-dependent or absent changes. That evidence does not establish a simple direct-GABA-agonist description or clinical equivalence to a benzodiazepine.

Does Selank cause withdrawal or dependence?

The available small, short clinical studies do not settle long-term dependence or withdrawal risk. One Selank paper studied morphine withdrawal in rats, which is a different question from withdrawal after Selank exposure. It cannot establish that Selank is free of dependence risk.

Does Selank lower cortisol?

The human studies reviewed here do not establish a reproducible cortisol-lowering effect. Changes in anxiety ratings, brain imaging or animal stress behavior do not by themselves show a change in human cortisol.

Is Selank FDA approved, and is a nasal spray equivalent to studied material?

Selank is not an FDA-approved medicine. FDA flags safety-information gaps and potential immunogenicity concerns for Selank acetate. A product sold as a nasal spray is not automatically equivalent to a clinical formulation; identity, composition, quality and evidence for that preparation remain separate questions.

Can Selank and Semax be combined?

They are different peptides. A human imaging study compared separate Selank, Semax and placebo groups; it did not test their combination. The evidence reviewed here does not establish an additive benefit or the safety of combining products. The dedicated Selank–Semax comparison explains their different identities and research histories.

References and primary sources

1. Konstantinopolsky MA et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine. 2022. PMID 36322304.
2. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID 32342318.
3. Vanhee C et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug testing and analysis. 2020. PMID 31667971.
4. Kolik LG et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine. 2019. PMID 31625062.
5. Vyunova TV et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters. 2018. PMID 30255741.
6. Povarov IS et al. Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons. Bulletin of experimental biology and medicine. 2017. PMID 28361410.
7. Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in pharmacology. 2017. PMID 28293190.
8. Kasian A et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural neurology. 2017. PMID 28280289.
9. Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in pharmacology. 2016. PMID 26924987.
10. Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015. PMID 26356395.
11. Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014. PMID 25176261.
12. Ashmarin IP et al. [A comparative analysis of distribution of glyprolines administered by various routes]. Bioorganicheskaia khimiia. 2008. PMID 18695718.
13. Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PMID 18577961.
14. Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PMID 18454096.
15. Zolotarev IuA et al. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Bioorganicheskaia khimiia. 2006. PMID 16637290.
16. Kozlovskaya MM et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and behavioral physiology. 2003. PMID 14969422.
17. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine. 2001. PMID 11550013.